SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Boston, Massachusetts, skyline over Quincy Market
Job Trends
21 Companies Miss Massachusetts Hiring Targets, Affecting Hundreds of Jobs
Nearly two dozen life sciences companies that were awarded Massachusetts tax incentives to create and retain about 1,000 combined jobs hit just 13% of that target in 2024. Ten awardees had reported layoffs last year, including Charles River Laboratories and Moderna.
November 13, 2025
 · 
6 min read
 · 
Angela Gabriel
Illustration of businessman running back around
Job Trends
When, Not If: Job Market Should Start Turning Around in Next Year or So, Experts Say
While most BioSpace LinkedIn poll respondents believe the job market won’t improve until at least 2027, two industry experts are optimistic a turnaround could start sooner. They discuss early signals of recovery and challenges that remain.
November 13, 2025
 · 
6 min read
 · 
Angela Gabriel
Poster collage of happy funky guy celebrating success wealth receive give crumpled banknotes isolated on drawing colorful background.
Funding
Biohaven Seeks $150 Million From Wall Street Following FDA Rejection
After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.
November 12, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
too many different pill of various blisters with different pills Medicines storage at home concept Medication storing. A pile of medicine in blister packs. Pharmaceutical blister packs.
Insights
Five Trends That Got Everyone Talking in Pharma and Biotech This Year
In 2025, landmark obesity drug deals, China’s biotech surge, and AI’s deeper integration into pharma operations drove a year of transformation and renewed momentum for life sciences.
November 12, 2025
 · 
5 min read
 · 
Jennifer C. Smith-Parker
Boss kick fired employee away form office. concept of lay off or underperform, failure or mistake
Layoffs
Metagenomi Chops 25% of Workforce, CEO To Advance Hemophilia A Program
The strategic initiative will extend Metagenomi’s cash runway into the fourth quarter of 2027. That same year, the company expects to generate initial Phase I data for its lead asset MGX-001 in hemophilia A.
November 12, 2025
 · 
2 min read
 · 
Tristan Manalac
3d fatty liver disease isolated on pink background. 3d illustration render
MASH
Altimmune Poised for $1B+ Opportunity as MASH Drug Aces Phase IIb
Altimmune’s pemvidutide showed “class-leading signals” in non-invasive assessments and has “potentially best-in-class tolerability,” according to analysts at H.C. Wainwright.
November 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Isometric businessman tightrope walker is on the rope. Teetering on the cable. Business challenge and risk concept. Simple minimal design. Trendy style graphic. Flat vector illustration.
Business
Phase III Fail Forces Neuphoria Into Strategic Review—With One Investor Offering a Takeover
Aside from offering to acquire all remaining shares of Neuphoria, existing investor Lynx1 Master Fund also announced its plan to nominate directors in the biotech’s upcoming board elections.
November 12, 2025
 · 
1 min read
 · 
Tristan Manalac
3d rendered illustration of hockey ice rink and goal. The puck is flying on goal.
Immunology and inflammation
Novartis, Vertex, More Optimizing Shots on Multiple Goals in Lucrative I&I Space
With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the third quarter, the pipeline-in-a-product strategy has never been more attractive.
November 12, 2025
 · 
6 min read
 · 
Heather McKenzie
Podcast
Pfizer Wins Metsera, Trump Strikes GLP-1 Pricing Deal, FDA Awards More Priority Vouchers
Pfizer seals the deal with Metsera for $10 billion after Novo Nordisk bowed out; President Donald Trump welcomes executives from Novo and Eli Lilly to the White House to announce that the companies’ GLP-1 medicines would be sold at a reduced cost; and the FDA grants the second round of priority review vouchers—primarily to already marketed drugs.
November 12, 2025
 · 
1 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS